4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow lanifibranor: new trials by email Literature Review of lanifibranor trials Research Report on lanifibranor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus Lanifibranor, Placebo, Empagliflozin - NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Inventiva Pharma | 39 | 2022-06-29 | 2026-09-09 |
| Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease Lanifibranor, Placebo - Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) | Phase 2 | Completed | University of Florida | 128 | 2018-08-14 | 2024-09-19 |
| Phase 2b Study in NASH to Assess IVA337 IVA337, Placebo - Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Inventiva Pharma | 247 | 2017-02-07 | 2023-07-19 |
| Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis IVA337, Placebo - Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | Inventiva Pharma | 145 | 2015-10-29 | 2019-03-04 |
Non-alcoholic Fatty Liver Disease (3) · Diabetes Mellitus, Type 2 (2) · Digestive System Diseases (1) · Fatty Liver (1) · Fibrosis (1) · Liver Diseases (1) · Scleroderma, Diffuse (1)
Inventiva Pharma (3) · University of Florida (1)
France (3) · United Kingdom (3) · United States (3) · Belgium (2) · Bulgaria (2) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · Slovenia (2) · Spain (2) · Switzerland (2) · Australia (1) · Austria (1) · Canada (1)
Christopher Denton, Professor (1) · Kenneth Cusi, MD (1) · Yannick Allanore, Professor (1)
PMID 33038502, PMID 34670042, PMID 38730247, PMID 39824443, PMID 40107637
2016 (1)